Analysis from DFZQ indicates that the recovery of global industry leaders signals a shift in the high-end medical device market towards a platform-based competition phase. Drawing on the strong performance of specific segments from Medtronic's FY2026 results, two key investment directions are highlighted: 1) Electrophysiology companies with robust comprehensive competitiveness amid the rapid growth of Pulsed Field Ablation (PFA) therapy; and 2) Surgical robotics companies that achieve sustained unit growth through differentiation in structural design and remote surgery, enabling them to build platform-based competitive moats.
CAS Business Growth Accelerates, PFA Competition Emphasizes Integrated Capabilities
Medtronic's Q4 FY2026 Cardiac Ablation Solutions (CAS) business grew 78% year-over-year, with the US market surging 124%, making it the strongest growth driver within the company's cardiovascular portfolio. This growth is no longer driven by a single product's volume but by the increasing penetration of PFA technology coupled with the gradual realization of a platform strategy. PulseSelect primarily addresses standard atrial fibrillation ablation cases, while Affera/Sphere-9 targets more complex procedures by leveraging integrated mapping and dual-energy capabilities. The industry is transitioning from the introduction phase of PFA to a stage of scaled application. Consequently, market competition is evolving from a focus on single-catheter performance to a contest of comprehensive capabilities, including mapping systems, energy platforms, clinical data, and channel coverage.
Hugo Robot Nears US Commercialization, Surgical Robotics Competition Moves Towards Platform Ecosystems
In December 2025, Hugo received FDA clearance for urological indications and is advancing expansions into general surgery and gynecology, clarifying its path to US commercialization. Hugo and da Vinci are not in a simple substitution relationship; they employ differentiated competitive strategies. Da Vinci maintains dominance in the global surgical robotics market through its long-established installed base, physician training programs, and broad range of indications. In contrast, Hugo aims to reduce overall hospital deployment costs and improve equipment utilization through a modular robotic arm architecture, an open console design, and its Touch Surgery digital platform (with DS1 installations growing 90% year-over-year and over 30% quarter-over-quarter). The competition in the surgical robotics industry is expected to evolve from a focus on individual device performance to a competition among platform ecosystems. Core competitive barriers will include the breadth of indication coverage, accumulation of clinical evidence, physician training systems, digital capabilities, and consumables business models. As the global market enters a phase with multiple vendors and platforms, hospital procurement logic may shift from single-brand purchases to multi-platform configurations to meet diverse surgical and cost management needs. In the long term, companies with complete product portfolios, continuous expansion of indications, and digital ecosystem strategies will be better positioned to capture greater market share.
Implications for Chinese Manufacturers: Competitive Logic Shifts from Product to Platform
The rapid growth of Medtronic's CAS business and the Hugo robot further validates the trend toward platformization in the high-end medical device sector. For the CAS segment, the global electrophysiology market is projected to grow from $8.8 billion in 2026 to $20.1 billion by 2034, representing a CAGR of 11.0%. For domestic electrophysiology companies, relying solely on a single catheter product will be insufficient to build long-term barriers. Platform-based manufacturers with synergistic layouts encompassing mapping systems, ablation equipment, and catheter products are better positioned to benefit from the industry's expansion. Regarding surgical robotics, the global market is forecast to grow from $9.2 billion in 2025 to $38.4 billion by 2034, a CAGR of 17%. Intuitive Surgical has already established a closed commercial ecosystem in the existing market. For Chinese companies seeking to break through as latecomers, differentiated platform development is crucial to creating unique competitive moats and capturing market share.
Risk Factors
Key risks include intensifying industry competition; potential delays in research, development, and clinical progress; and challenges related to overseas expansion and geopolitical factors.